Clinical trial · Observational
China Adrenal Disease Registry
China Adrenal Disease Registry Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide. In order to meet all the therapeutic challenges in adrenal disease in China, CASE was founded in 2020. The objective of CASE is to launch an adrenal disease management model based on the Internet health information platform which allows the application and evaluation of adrenal disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of adrenal disease, diagnosis, and treatment.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adrenal Adenoma | Adrenal Cortical Adenoma | ALIAS | 0.90 |
| Adrenal Carcinoma | — | UNRESOLVED | — |
| Adrenal Incidentaloma | — | UNRESOLVED | — |
| Aldosteronism | — | UNRESOLVED | — |
| Congenital Adrenal Hyperplasia | — | UNRESOLVED | — |
| Cushing Syndrome | — | UNRESOLVED | — |
| Hypoadrenalism | — | UNRESOLVED | — |
| Pheochromocytoma | Adrenal Gland Pheochromocytoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Percentage of adrenal diseases in China
- timeFrame
- through study completion, an average of 1 year
- measure
- Number of participants with complication of adrenal diseases in China
- timeFrame
- through study completion, an average of 1 year
Secondary outcomes (10)
- measure
- concentration of aldosterone
- timeFrame
- through study completion, an average of 1 year
- measure
- concentration of cortisol
- timeFrame
- through study completion, an average of 1 year
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 16 years old and ≤ 75 years 2. Patients diagnosed with adrenal associated diseases, including cushing syndrome, primary aldosteronism, primary hypoadrenalism, congenital adrenal hyperplasia and adrenal adenomas, incidentalomas, and carcinomas, pheochromocytoma, etc. 3. Provide written informed consent 4. Satisfactory compliance Exclusion Criteria: 1. Patients with significantly reduced life expectancy (less than 2 years) 2. With Drug abuse 3. With AIDS or syphilis or infectious diseases such as viral tuberculosis in active phase at enrollment
References
Publications (0)
Data not yet available